Laxxon Medical’s Innovative Levodopa / Carbidopa (LXM.5) Oral Dosage Form Demonstrates Significantly Higher Bioavailability (>380%) Compared to Sinemet®, Study Results Published in the Journal Pharmaceutics
Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced the publication of a new study in the Journal Pharmaceutics (MDPI) that highlights the effectiveness of its proprietary carbidopa/levodopa formulations (LXM.5) for the treatment of Parkinson's disease. The pharmacokinetic study demonstrated that Laxxon’s novel dosage forms significantly improved bioavailability compared to Sinemet® (carbidopa/levodopa), a current standard treatment option for Parkinson’s disease.
Laxxon Medical to Attend BIO-Europe and Jefferies Healthcare Conference World Premier Life Science Partnering Events
Laxxon Medical, a leading pharmaceutical technology company, pioneering a new generation of advanced oral drug delivery systems, today announced that it will be attending BIO-Europe 2025 and the Jefferies Healthcare Conference, two of the world’s premier partnering events for the Life Sciences industry.
Evonik Industries and Laxxon Medical see future in 3D screen printed pharmaceuticalsNEW YORK, NY / ACCESSWIRE / March 8, 2022 / Evonik Industries AG, a leading global supplier of specialty chemicals, announced Monday their venture capital company's strategic investment with Laxxon Medical Corporation. Laxxon Medical is a U.S. based company whose patented 3D screen printing technology enables the controlled release of multiple active pharmaceutical ingredients within a single tablet. Evonik's specialized polymers ensure targeted
'Game Changing' Technology Enables QR Code Integration with 3D Screen PrintingNEW YORK, NY / ACCESSWIRE / February 16, 2022 / A study in the Biomedical Journal of Scientific & Technical Research (BJSTR) reports that advances in 3D screen printing allow for mass customization and in-drug labeling of pharmaceuticals with unique identifying information, such as Quick Response (QR) codes, which have been shown to reduce medication errors, improve patient safety, and provide a viable mechanism for remote patient monitoring
Laxxon Medical to Participate in the 24th Annual Needham Virtual Growth ConferenceNEW YORK, NY / ACCESSWIRE / January 7, 2022 / Laxxon Medical Corporation announced today that management will conduct one-on-one meetings at the 24th Annual Needham Growth Conference, which will be held virtually from Jan 10-14, 2022. About Laxxon Medical Corporation Laxxon Medical holds the exclusive worldwide rights to the patented use and application of 3D screen printing technology for the development, manufacture and commercialization of
